This COVID-19 Shot Stock Could Have Eye Disease Gene Therapy As Significant Driver, Mizuho Analyst Says

  • Mizuho initiated coverage on Ocugen Inc OCGN with a Buy rating and a price target of $5, reflecting an upside of almost 115%.
  • Mizuho views Ocugen as a high-risk, high-reward opportunity.
  • While the lead asset, a COVID-19 vaccine (Covaxin), offers potential near-term cash flow to help offset operational costs, Mizuho believes OCU400, a Phase 1/2 gene therapy for eye disease, is a more significant value driver for the company.
  • According to the analyst, the current stock price primarily reflects the value of Covaxin. 
  • Related: Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years.
  • "If approved, we believe COVAXIN could be attractive to individuals in the US seeking a broad antibody response against multiple antigens or waiting for a traditionally made COVID-19 vaccine due to their discomfort with mRNA vaccines," Mizuho writes.
  • The stock price incorporates little to no value for OCU400, setting up a favorable risk/reward going into the first human efficacy data readout for OCU400 in 1H23.
  • The analyst models a 20% probability of success sales of $455 million ($2.3 billion unadjusted) in 2030 for five key inherited retinal diseases (with cumulative sales of $3.3 billion ($16.3 billion unadjusted) for 2026-2035E). 
  • Price Action: OCGN shares are up 3.85% at $2.43 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst ColorBiotechNewsPenny StocksHealth CarePrice TargetInitiationSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccinegene therapy
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!